You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 9, 2025

Selexipag - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for selexipag and what is the scope of freedom to operate?

Selexipag is the generic ingredient in two branded drugs marketed by Actelion, Alembic, and Zydus Lifesciences, and is included in four NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selexipag has one hundred and fifty-three patent family members in thirty-nine countries.

There are two drug master file entries for selexipag. Two suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for selexipag
Recent Clinical Trials for selexipag

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Newcastle Upon-TynePhase 4
Sheffield Teaching Hospitals NHS Foundation TrustPhase 4
University of GlasgowPhase 4

See all selexipag clinical trials

Generic filers with tentative approvals for SELEXIPAG
Applicant Application No. Strength Dosage Form
⤷  Try for Free⤷  Try for Free1600MCGTABLET;ORAL
⤷  Try for Free⤷  Try for Free1400MCGTABLET;ORAL
⤷  Try for Free⤷  Try for Free1200MCGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for selexipag
Paragraph IV (Patent) Challenges for SELEXIPAG
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
UPTRAVI For Injection selexipag 1.8 mg/vial 214275 1 2022-07-29
UPTRAVI Tablets selexipag 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg and 1.6 mg 207947 4 2019-12-23

US Patents and Regulatory Information for selexipag

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion UPTRAVI selexipag POWDER;INTRAVENOUS 214275-001 Jul 29, 2021 RX Yes Yes 7,205,302 ⤷  Try for Free Y Y ⤷  Try for Free
Actelion UPTRAVI selexipag TABLET;ORAL 207947-004 Dec 21, 2015 AB RX Yes No 10,828,298 ⤷  Try for Free Y ⤷  Try for Free
Actelion UPTRAVI selexipag TABLET;ORAL 207947-007 Dec 21, 2015 AB RX Yes No 9,173,881 ⤷  Try for Free ⤷  Try for Free
Actelion UPTRAVI selexipag TABLET;ORAL 207947-003 Dec 21, 2015 AB RX Yes No 9,173,881 ⤷  Try for Free ⤷  Try for Free
Zydus Lifesciences SELEXIPAG selexipag TABLET;ORAL 214302-007 Dec 21, 2022 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Zydus Lifesciences SELEXIPAG selexipag TABLET;ORAL 214302-004 Dec 21, 2022 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Actelion UPTRAVI selexipag TABLET;ORAL 207947-006 Dec 21, 2015 RX Yes No 9,284,280 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for selexipag

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Janssen Cilag International NV Uptravi selexipag EMEA/H/C/003774
Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.,
Authorised no no no 2016-05-12
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for selexipag

Country Patent Number Title Estimated Expiration
Taiwan I316055 ⤷  Try for Free
Norway 2315587 ⤷  Try for Free
Brazil PI0209249 agonista de receptor de pgi2, inibidor de agregacao de plaqueta, agentes terapeuticos e derivados de composto heterociclico ⤷  Try for Free
Mexico 346318 CRISTALES. (CRYSTALS.) ⤷  Try for Free
Ukraine 124002 ТВЕРДИЙ ПРЕПАРАТ, ЩО МІСТИТЬ 2-{4-[N-(5,6- ДИФЕНІЛПІРАЗИН-2-ІЛ)-N-ІЗОПРОПІЛАМІНО]БУТИЛОКСИ}-N-(МЕТИЛСУЛЬФОНІЛ)АЦЕТАМІД (PHARMACEUTICAL COMPOSITION CONTAINING 2-{4-[N-(5,6- DIPHENYLPYRAZIN-2-YL)-N-ISOPROPYLAMINO]BUTYLOXY}-N- (METHYLSULFONYL)ACETAMIDE) ⤷  Try for Free
Japan 6825574 ⤷  Try for Free
Germany 60217674 ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for selexipag

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1400518 93266 Luxembourg ⤷  Try for Free PRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519
1400518 132016000106856 Italy ⤷  Try for Free PRODUCT NAME: SELEXIPAG O UN SUO SALE(UPTRAVI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1083, 20160519
2447254 C20180012 00263 Estonia ⤷  Try for Free PRODUCT NAME: SELEKSIPAAG;REG NO/DATE: EU/1/15/1083 19.05.2016
1400518 2016/047 Ireland ⤷  Try for Free PRODUCT NAME: SELEXIPAG OR SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1083 20160512
1400518 CR 2016 00048 Denmark ⤷  Try for Free PRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519
2447254 PA2018008,C2447254 Lithuania ⤷  Try for Free PRODUCT NAME: SELEKSIPAGAS; REGISTRATION NO/DATE: EU/1/15/1083 20160512
2447254 PA2018008 Lithuania ⤷  Try for Free PRODUCT NAME: SELEKSIPAGAS; REGISTRATION NO/DATE: EU/1/15/1083 20160512
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory of Selexipag

Last updated: July 4, 2025

Introduction

Selexipag, a targeted therapy for pulmonary arterial hypertension (PAH), has reshaped treatment options since its FDA approval in 2015. As a prostacyclin receptor agonist marketed as Uptravi by Johnson & Johnson, it addresses a critical unmet need in a rare but life-threatening condition. This analysis examines the evolving market dynamics and financial trajectory of selexipag, offering insights for business professionals navigating the pharmaceutical landscape. With PAH prevalence rising and competition intensifying, understanding selexipag's position is essential for informed investment and strategic decisions.

Overview of Selexipag

Selexipag stands out as a once-daily oral treatment that dilates blood vessels and reduces the risk of PAH progression. Developed by Actelion Pharmaceuticals and acquired by Johnson & Johnson in 2017 for $30 billion, it targets the IP prostacyclin receptor to improve patient outcomes. Clinical trials, including the pivotal GRIPHON study, demonstrated its efficacy in delaying disease worsening, making it a cornerstone for PAH management.

The drug's mechanism involves selective activation of the prostacyclin pathway, which differentiates it from older therapies like epoprostenol. This specificity enhances tolerability and convenience, driving adoption in a market where patient compliance is a persistent challenge. As PAH affects approximately 15-50 people per million globally, selexipag's niche focus has fueled its growth, with annual sales exceeding $1 billion in recent years.

Current Market Dynamics

The PAH market has expanded rapidly, projected to reach $8.5 billion by 2028, according to industry forecasts. Selexipag commands a significant share, driven by increasing disease awareness and an aging population. In the U.S. and Europe, where PAH diagnoses have risen by 20% over the past five years, selexipag's availability through specialized centers bolsters its market penetration.

Competition remains fierce, with rivals like Gilead Sciences' remodulin and Merck's bosentan challenging selexipag's dominance. However, selexipag differentiates itself through its oral formulation and lower risk of side effects, capturing about 30% of the PAH prescription market. Regulatory factors, such as FDA fast-track designations, have accelerated its global rollout, with approvals in over 50 countries enhancing export opportunities for Johnson & Johnson.

Generic threats loom as patents near expiration. Selexipag's core patent, set to expire in 2026 in the U.S., could invite biosimilars, potentially eroding market share by 15-20%. Yet, Johnson & Johnson's defensive strategies, including secondary patents on formulations, may extend exclusivity. Pricing pressures from payers and government negotiations in markets like Germany and Japan further shape dynamics, with selexipag's list price around $9,000 per month in the U.S. facing scrutiny.

Global supply chain disruptions, exacerbated by the COVID-19 pandemic, have impacted selexipag's availability, highlighting vulnerabilities in raw material sourcing from Asia. Despite this, demand resilience in emerging markets like China and India, where PAH incidence is climbing, offers growth avenues. Johnson & Johnson's partnerships with local distributors have doubled selexipag's reach in Asia-Pacific over the last three years.

Financial Performance of Selexipag

Selexipag's financial trajectory reflects Johnson & Johnson's strategic prowess, with Uptravi generating $1.2 billion in global sales in 2023—a 12% increase from the previous year. This growth stems from expanded indications and market expansion, particularly in Europe and Asia, where sales rose 18%. The drug's contribution to Johnson & Johnson's cardiovascular portfolio has been pivotal, accounting for 5% of the company's total revenue in 2023.

Profit margins for selexipag remain robust, with gross margins exceeding 80%, thanks to efficient manufacturing and premium pricing. However, R&D investments, totaling $500 million annually for PAH innovations, temper net profits. Financial analysts project selexipag's revenue to peak at $1.5 billion by 2025, before a potential dip post-patent expiration. This trajectory aligns with broader pharmaceutical trends, where blockbuster drugs like selexipag drive earnings but face lifecycle management challenges.

Johnson & Johnson's acquisition of Actelion amplified selexipag's financial upside, integrating it into a diversified pipeline. In Q4 2023 earnings calls, executives highlighted selexipag as a key growth driver, with forecasts of 10% annual revenue growth through 2026. Currency fluctuations and inflation have introduced volatility, reducing profits by 5% in international markets, yet strategic hedging mitigates these risks.

Investor sentiment toward selexipag remains positive, evidenced by Johnson & Johnson's stock uptick of 15% since 2022. This optimism hinges on ongoing trials exploring selexipag's use in combination therapies, potentially unlocking $500 million in additional revenue streams. Financial metrics, such as a return on investment exceeding 20% for selexipag-related assets, underscore its value in a portfolio increasingly focused on specialty pharmaceuticals.

Patent Landscape and Future Outlook

Selexipag's patent portfolio, comprising over 20 granted patents worldwide, safeguards its market exclusivity until 2026 in major regions. Key patents cover the drug's chemical composition and delivery methods, with extensions possible through pediatric exclusivity in the U.S. This landscape deters generic entrants, maintaining pricing power and revenue stability.

Looking ahead, Johnson & Johnson is pursuing label expansions, including trials for PAH in pediatric populations, which could extend market lifespan. Analysts predict that even with generics entering post-2026, selexipag could retain 40% market share through branded advantages. Mergers and acquisitions in the PAH space, such as recent deals by competitors, may influence selexipag's trajectory, potentially leading to partnerships that enhance its distribution.

Economic factors, including inflation and healthcare budget constraints, pose risks. However, selexipag's role in value-based care models, where outcomes justify costs, positions it favorably. By 2030, the drug's financial path could evolve toward sustained profitability if Johnson & Johnson innovates with next-generation therapies, ensuring long-term dominance in PAH treatment.

Competitive Landscape

In the PAH arena, selexipag competes against established players like Revatio from Pfizer and Orenitram from United Therapeutics. While these alternatives focus on phosphodiesterase inhibitors, selexipag's prostacyclin-based approach offers superior efficacy in certain subgroups, securing physician preference. Market share data indicates selexipag leads in oral therapies, with 35% of new PAH prescriptions in 2023.

Strategic alliances, such as Johnson & Johnson's collaborations with research institutions, bolster selexipag's edge. Competitors' pipeline developments, including novel biologics, could challenge this, but regulatory hurdles often delay their impact. Pricing strategies, with selexipag's discounts in competitive bids, help maintain volume despite reimbursement challenges.

Conclusion

Selexipag's market dynamics and financial trajectory highlight its resilience in a specialized therapeutic area. As PAH prevalence grows and innovation continues, the drug remains a vital asset for Johnson & Johnson, balancing growth with impending challenges.

Key Takeaways

  • Selexipag drives significant revenue for Johnson & Johnson, with 2023 sales reaching $1.2 billion and projections of further growth before patent expiry.
  • The PAH market is expanding at 8-10% annually, but competition and generics could reduce selexipag's share post-2026.
  • Strategic patent extensions and label expansions position selexipag for long-term profitability despite economic pressures.
  • Global demand in emerging markets offsets supply chain risks, enhancing financial stability.
  • Investors should monitor R&D outcomes, as they could add $500 million in revenue through new indications.

FAQs

  1. What factors are driving the growth of selexipag's market?
    Selexipag's growth stems from rising PAH diagnoses, its convenient oral dosing, and expanded global approvals, particularly in Asia-Pacific regions.

  2. How will patent expiration affect selexipag's financials?
    Expected in 2026, patent expiry may introduce generics, potentially cutting revenue by 15-20%, but secondary patents could mitigate this impact.

  3. What role does selexipag play in Johnson & Johnson's portfolio?
    As a top performer in the cardiovascular segment, selexipag contributes 5% to annual revenue and supports the company's focus on rare disease therapies.

  4. How does selexipag compare to other PAH treatments financially?
    Selexipag outperforms competitors in gross margins due to its premium pricing and lower manufacturing costs, though it faces similar reimbursement challenges.

  5. What future developments could influence selexipag's trajectory?
    Ongoing trials for combination therapies and pediatric use could extend its market exclusivity and boost revenue beyond current projections.

Sources

  1. Johnson & Johnson. (2023). Annual Financial Report. Retrieved from Johnson & Johnson investor relations.
  2. IQVIA Institute. (2024). Global Use of Medicines Report, focusing on PAH market projections. Retrieved from IQVIA official publications.
  3. U.S. Food and Drug Administration. (2015). Approval Letter for Selexipag. Retrieved from FDA website.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.